ArticleAmerican journal of respiratory and critical care medicine2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
16.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Exploring the utilisation and effectiveness of implementation science strategies by cystic fibrosis registries for healthcare improvement: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis.iScience · 2026Article
- Pediatric hepatic laboratory reporting with CFTR modulators: a FAERS pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- SOLAR: a noninterventional study of outcomes over the long term of people with cystic fibrosis (CF) aged ≥6 years treated with elexacaftor/tezacaftor/ivacaftor using data from the French CF Registry.ERJ open research · 2026Article
- Targeted Therapy for Restoring CFTR Activity: From Experimental to Clinical Features.International journal of molecular sciences · 2026Review
- Comparison of Single-Breath and Multi-Breath Xe-MRI in the Longitudinal Assessment of Treatment in Children With Cystic Fibrosis.Journal of magnetic resonance imaging : JMRI · 2026Article
- The endocrine complications of cystic fibrosis.Nature reviews. Endocrinology · 2026Review
- Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry.ERJ open research · 2026Article
- Review
- Prevalence and risk factors for recurrent Staphylococcus aureus small-colony variants in people with cystic fibrosis followed at the Tuscan Regional Reference Center.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Xenon-129 magnetic resonance imaging detects ongoing ventilation improvements in people with cystic fibrosis receiving highly effective modulator therapy.Annals of the American Thoracic Society · 2026Article
- The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Long-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor on Nocturnal Cardiorespiratory Polygraphy Parameters in Patients with Cystic Fibrosis: A Prospective Study.Life (Basel, Switzerland) · 2025Article
- Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.The European respiratory journal · 2025Observational
- A Review of Newborn Screening Programs for Cystic Fibrosis: Are Current Protocols Appropriate for Canada's Diverse Population?Pediatric pulmonology · 2025Article
- Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis: No Longer "If" but a Question of "When" to Start.American journal of respiratory and critical care medicine · 2025Article
- An alternative view of changes in lung function among people with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025Article
- Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 10 institutions in 5 countries.
Claire WainwrightQueensland Children's Hospital, South Brisbane, Queensland, Australia.
Susanna A McColleyAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Paul McNallyChildren's Health Ireland, Dublin, Ireland.ORCID 0000-0001-7102-1712
Michael PowersOregon Health & Sciences University, Portland, Oregon.
Felix RatjenUniversity of Toronto, Toronto, Ontario, Canada.
Jonathan H RaymentUniversity of British Columbia, Vancouver, British Columbia, Canada.
George Retsch-BogartUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Erica RoeschUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio.
Neil AhluwaliaVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Anna ChinVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Chenghao ChuVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Mengdi LuVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Prema MenonVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
David WaltzVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Tanya WeinstockVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Laura ZelazoskiVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Jane C DaviesNational Heart and Lung Institute, Imperial College London, London, United Kingdom; and.ORCID 0000-0003-3506-1199
Vertex Pharmaceuticals (United States) · USNorthwestern University · USOregon Health & Science University · USRoyal Brompton Hospital · GBRoyal College of Surgeons in Ireland · IEThe University of Queensland · AUUniversity Hospitals of Cleveland · USUniversity of British Columbia · CAUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CA
Funding
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4MNCATS NIH HHS UL1 TR002369
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cystic FibrosisAdultAllelesAminophenolsBenzodioxolesChildChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorHumansIndolesMutationPyrazolesPyridinesPyrrolidinesQuinolonesAminophenolsBenzodioxolesChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorelexacaftorIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolonestezacaftorCFTR modulatorchildrenelexacaftor/tezacaftor/ivacaftorlong-term extension study
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.